GeneFluidics' detection technology platform can be leveraged to detect and quantify analyte critical to a wide range of applications including in vitro diagnostics, animal diagnostics, biothreat detection, and environmental monitoring.
In each of these industries, there is considerable need for faster, easier, and more efficient methods for analyte quantification.
We feel that technologies that can turn complex operations into simple ones are winners and as such believe that our platform will have broad impact.
Click the buttons above to read more.
Accuracy, reliability and speed are essential to in vitro diagnostics. GeneFluidics develops robust detection platforms and point-of-care research systems to deliver accurate and prompt results for research in medicine and other life sciences. In close collaboration with physicians in urology, pediatric pathology and oral oncology, GeneFluidics is working to develop and optimize products that will be reliable and easy-to-use in hospital and clinic settings*.
* GeneFluidics' products are currently for Research Use Only -- Not for use in diagnostic procedures.
Driven by injudicious prescription of antibiotics, emergence of drug-resistant pathogens is a growing threat to global health. Typical microbial analysis of bacterial infections relies on a culturing process requiring one to three days before results are available. This often forces clinicians to prescribe antibiotics before test results are available.
Utilizing GeneFluidics’ detection technology, rapid antimicrobial susceptibility testing (AST) is possible. Capable of providing susceptibility data within hours rather than days, the platform could enable clinicians to treat patients based on accurate pathogen identification and resistance information without promoting the growth of drug-resistant pathogens.
The threat of domestic biological attacks has led to an urgent call for fast, effective and accurate biothreat agent detection. GeneFluidics’ detection technology can offer rapid, sensitive methods for monitoring our food, water and soil for incidental contamination by harmful pathogens.
GeneFluidics is currently working with the US Army Edgewood Chemical Biological Center to develop biodefense diagnostic systems for deployment in both fixed laboratories and mobile field units.
GeneFluidics' detection technology and point-of-care platforms can provide solutions for diagnosing companion animals as well as food animals. By enabling point-of-care testing, veterinarians can gather diagnostic information promptly for accurate diagnosis and appropriate treatment prescription. In the food animal segment, field-testing can improve infectious disease control, animal health, and public health.
